Search results
Feb 17, 2022 · For full-year 2021, net income attributable to Baxter totaled $1.3 billion, or $2.53 per diluted share, increasing 19% on a U.S. GAAP basis compared to the prior year.
Feb 9, 2023 · The accompanying schedules include additional details on sales performance by product categories and segments. For full-year 2022, net income (loss) attributable to Baxter totaled ($2.4 billion), or ($4.83) per diluted share on a U.S. GAAP basis.
Feb 23, 2022 · Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2021, and provided its financial guidance for full year and first quarter 2022.
- Baxter International Inc
Feb 9, 2023 · Baxter Reports Fourth-Quarter and Full-Year 2022 Results. Fourth-quarter sales of $3.9 billion increased 11% on a reported basis, 17% on a constant currency basis and 2% on an operational basis 1. Fourth-quarter U.S. GAAP diluted earnings per share (EPS) of $0.36 and adjusted diluted EPS of $0.88.
2022 Financial Outlook For full-year 2022: Baxter now expects U.S. GAAP earnings of $2.35 to $2.43 per diluted share and adjusted earnings, before special items, of $4.12 to $4.20 per diluted share. The company expects sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant
Information regarding Baxter’s recent announcements, upcoming & past events, and other useful resources for investors. Baxter's Annual Chairman Letter, Proxy Statement and Form 10-K filings sorted by year.
People also ask
How much did Baxter make in 2022?
What is Baxter's fourth-quarter 2021 earnings outlook?
What is Baxter's financial outlook for 2023?
What does Baxter expect in 2023?
Baxter International Inc., through its subsidiaries, provides a broad portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable
